Recent news releases
-
Aug 9, 2023 Voluntary Recall of seven ( 7 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard)
-
Aug 9, 2023 Voluntary Recall of three ( 3 ) lots of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP)
-
Apr 3, 2023 SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals
-
Feb 1, 2023 Voluntary Recall of one ( 1 ) lot of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg - Lot PY1904
-
Dec 16, 2022 Accessa becomes the patient support program manager for Apotex Inc.'s Apo-Deferasirox™ and Apo-Deferasirox (Type J)™ products.
-
Sep 28, 2022 SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals
-
Jul 27, 2022 Voluntary Recall of four ( 4 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg
-
Jul 20, 2022 First Generic Alternative to Eliquis® Now Available in Canada
-
May 17, 2022 Apotex Launches Affordable Generic Option to Treat Relapsing Remitting Multiple Sclerosis
-
Apr 26, 2022 Voluntary Recall of five ( 5 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg.